HbA1c significantly improved in basal-bolus treated type 2 diabetes after flash glucose monitoring use for 3–6 months compared to SMBG (Diabetes Research and Clinical Practice)
Diabetes News
Tag: Type 2 Diabetes
Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes
Empagliflozin thus ameliorates the “cardiac energy-deficient” state, regresses adverse myocardial cellular remodeling, and improves cardiac function, offering therapeutic opportunities to prevent or modulate HF in T2D (Diabetes)
Impact of COVID-19 Vaccination on Glycemia in Individuals With Type 1 and Type 2 Diabetes: Substudy of the COVAC-DM Study
Our data revealed that COVID-19 vaccination per se did not change glycemic control in people with diabetes. Of note, on days on which side effects were present, a deterioration of glycemia was observed in people with type 1 diabetes (Diabetes Care)
Effect of blood lipid variability on mortality in patients with type 2 diabetes: a large single-center cohort study
Blood lipid variability except for triglyceride variability was associated with all-cause and cardiovascular mortality in patients with type 2 diabetes (Cardiovascular Diabetology)
Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
Tirzepatide reduces body weight and improves glycemic control and uniquely modulates metabolites associated with T2D risk and metabolic dysregulation in a direction consistent with improved metabolic health (Journal of Clinical Endocrinology & Metabolism)
Type 2 diabetes in adults: management
In November 2021, we reviewed the evidence on SGLT2 inhibitors for adults with type 2 diabetes and chronic kidney disease, and made new recommendations (NICE)
Type 2 diabetes in adults: management – glucose monitoring
Consultation documents (NICE)
Diabetes (type 1 and type 2) in children and young people: diagnosis and management – glucose monitoring
Consultation documents (NICE)
Type 2 diabetes in adults
Type 2 diabetes in adults – everything NICE says in an interactive flowchart (NICE)
Adiponectin gene polymorphisms and risk of type 2 diabetes: an updated evidence for meta-analysis
Collectively, our findings demonstrated a positive association between ADIPOQ + 276 G > T polymorphism with increased risk of T2D in male individuals with European ethnicity (Diabetology & Metabolic Syndrome)
Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis
Despite some gender differences in baseline characteristics, Gla-300 treatment improved glycaemic control, with overall low hypoglycaemia incidences in both men and women. However, women had statistically significantly lower HbA1c reductions than men, although these differences were clinically modest (Diabetes Therapy)
Utilization of glucagon-like peptide-1 receptor agonists and changes in clinical characteristics in type 2 diabetes mellitus patients by chronic kidney disease stage in Japan
The utilization of GLP-1 RA has been increasing over the past decade, and GLP-1 RAs have been used in patients with limited treatment options, such as the elderly or those with CKD. In T2DM patients with CKD, the persistence proportion of GLP-1 RAs was not low, and the renal dysfunction may be moderated by GLP-1 RA initiation (Diabetes, Obesity and Metabolism)
A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study
The analysis of data from the LEADER trial demonstrated that higher rates of NSHEs were associated with both a higher risk of severe hypoglycaemia and adverse cardiovascular outcomes in individuals with type 2 diabetes (Diabetologia)
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
The aim of the review is to highlight the current perspectives of the pathophysiology of heart failure as it pertains to type 2 diabetes (Cardiovascular Diabetology)
When and how to deintensify type 2 diabetes care
Deintensifying type 2 diabetes care can include deprescribing and reducing diabetes-specific assessments that no longer improve quality of life of older adults (BMJ)
Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early-phase study
URLi demonstrated accelerated insulin lispro absorption and greater postprandial glucose reduction at different meal-to-dose timings compared with Humalog and was well tolerated in patients with T2D (Diabetes, Obesity and Metabolism)
Diabetes: Concepts of β-Cell Organ Dysfunction and Failure Would Lead to Earlier Diagnoses and Prevention
There is a potential to identify both T2D and T1D at stages well before the onset of currently recognized clinical disease (Diabetes)
Factors Associated with Adherence to Clinical Practice Guidelines for Patients with Type 2 Diabetes Mellitus: Results of a Spanish Delphi Consensus
Nonadherence to CPGs on T2DM is a multifactorial problem but the existence multiple CPGs, the lack of time, the therapeutic inertia, and insufficient human resources have been identified as factors limiting adherence. Hypoglycemia continues to be a barrier for achievement of targets recommended by CPGs (Journal of Diabetes Research)
The importance of addressing multiple risk markers in type 2 diabetes: results from the LEADER and SUSTAIN 6 trials
In persons with type 2 diabetes, improvements in ≥2 risk markers conferred cardiovascular risk reduction versus none or 1 improved risk marker. The nephropathy risk decreased with improvement in more risk markers. These findings stress the importance of multifactorial interventions targeting all risk markers (Diabetes, Obesity and Metabolism)
Incidence Rates and Predictors of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes: Results from the Longitudinal Global DISCOVER Study
In this global study, both the prevalence and 3-year incidence of vascular complications were high in patients with relatively short T2D duration, highlighting the need for early risk-factor modification (American Heart Journal)
- 1
- 2
- 3
- …
- 57
- Next Page »
Glycosmedia is also available as an App: